Acurx Pharmaceuticals Inc ACXP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
2.14quote price arrow down-0.06 (-2.73%)
Volume
78,424
52 week range
1.17 - 8.82
Loading...
  • Open2.21
  • Day High2.32
  • Day Low2.13
  • Prev Close2.20
  • 52 Week High8.82
  • 52 Week High Date10/12/23
  • 52 Week Low1.17
  • 52 Week Low Date10/02/23

Key Stats

  • Market Cap33.72M
  • Shares Out15.76M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta-1.89
  • YTD % Change-43.6

KEY STATS

  • Open2.21
  • Day High2.32
  • Day Low2.13
  • Prev Close2.20
  • 52 Week High8.82
  • 52 Week High Date10/12/23
  • 52 Week Low1.17
  • 52 Week Low Date10/02/23
  • Market Cap33.72M
  • Shares Out15.76M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta-1.89
  • YTD % Change-43.6

RATIOS/PROFITABILITY

  • EPS (TTM)-1.14
  • P/E (TTM)-1.88
  • Fwd P/E (NTM)-2.21
  • EBITDA (TTM)-14.578M
  • ROE (TTM)-243.33%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/15/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Acurx Pharmaceuticals Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research...
Robert Deluccia
Executive Chairman, Co-Founder, Managing Partner, Executive Director
David Luci
President, Chief Executive Officer, Co-Founder, Managing Director
Address
259 Liberty Avenue
Staten Island, NY
10305
United States

Top Peers

SYMBOLLASTCHG%CHG
IINN
Inspira Technologies Oxy BHN Ltd
1.95+0.07+3.72%
VIRX
Viracta Therapeutics Inc
0.8201+0.0005+0.061%
NGNE
Neurogene Inc
33.71-0.77-2.23%
INKT
Mink Therapeutics Inc
0.9525-0.0375-3.7879%
ACHL
Achilles Therapeutics PLC
0.7818+0.0318+4.24%